Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 330

1.

Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.

Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Miossec P, Mukherjee B, Shah VN.

Diabetes Technol Ther. 2020 Mar 31. doi: 10.1089/dia.2020.0008. [Epub ahead of print]

PMID:
32068436
2.

Effects of Methotrexate Alone or Combined With Arthritis-Related Biotherapies in an in vitro Co-culture Model With Immune Cells and Synoviocytes.

Noack M, Miossec P.

Front Immunol. 2019 Dec 20;10:2992. doi: 10.3389/fimmu.2019.02992. eCollection 2019.

3.

Interleukin-17 and lupus: enough to be a target? For which patients?

Robert M, Miossec P.

Lupus. 2020 Jan;29(1):6-14. doi: 10.1177/0961203319891243. Epub 2019 Dec 2.

PMID:
31791181
4.

Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages.

Coutant F, Miossec P.

Curr Opin Rheumatol. 2020 Jan;32(1):57-63. doi: 10.1097/BOR.0000000000000664.

PMID:
31644463
5.

The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.

Sieper J, Poddubnyy D, Miossec P.

Nat Rev Rheumatol. 2019 Dec;15(12):747-757. doi: 10.1038/s41584-019-0294-7. Epub 2019 Sep 24. Review.

PMID:
31551538
6.

Biological Applications and Toxicity Minimization of Semiconductor Quantum Dots.

Filali S, Pirot F, Miossec P.

Trends Biotechnol. 2020 Feb;38(2):163-177. doi: 10.1016/j.tibtech.2019.07.013. Epub 2019 Aug 28. Review.

PMID:
31473014
7.

Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO).

Biver E, Berenbaum F, Valdes AM, Araujo de Carvalho I, Bindels LB, Brandi ML, Calder PC, Castronovo V, Cavalier E, Cherubini A, Cooper C, Dennison E, Franceschi C, Fuggle N, Laslop A, Miossec P, Thomas T, Tuzun S, Veronese N, Vlaskovska M, Reginster JY, Rizzoli R.

Ageing Res Rev. 2019 Nov;55:100946. doi: 10.1016/j.arr.2019.100946. Epub 2019 Aug 19. Review.

8.

Additive or Synergistic Interactions Between IL-17A or IL-17F and TNF or IL-1β Depend on the Cell Type.

Noack M, Beringer A, Miossec P.

Front Immunol. 2019 Jul 23;10:1726. doi: 10.3389/fimmu.2019.01726. eCollection 2019.

9.

Systemic effects of IL-17 in inflammatory arthritis.

Beringer A, Miossec P.

Nat Rev Rheumatol. 2019 Aug;15(8):491-501. doi: 10.1038/s41584-019-0243-5. Epub 2019 Jun 21. Review.

PMID:
31227819
10.

Two phase kinetics of the inflammatory response from hepatocyte-peripheral blood mononuclear cell interactions.

Beringer A, Molle J, Bartosch B, Miossec P.

Sci Rep. 2019 Jun 10;9(1):8378. doi: 10.1038/s41598-019-44840-w.

11.

Cryoglobulins Today: Detection and Immunologic Characteristics of 1,675 Positive Samples From 13,439 Patients Obtained Over Six Years.

Kolopp-Sarda MN, Nombel A, Miossec P.

Arthritis Rheumatol. 2019 Nov;71(11):1904-1912. doi: 10.1002/art.41003. Epub 2019 Sep 20.

PMID:
31136095
12.

Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients.

Rinaudo-Gaujous M, Blasco-Baque V, Miossec P, Gaudin P, Farge P, Roblin X, Thomas T, Paul S, Marotte H.

J Clin Med. 2019 May 26;8(5). pii: E751. doi: 10.3390/jcm8050751.

13.

IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells.

Beringer A, Miossec P.

Clin Exp Immunol. 2019 Oct;198(1):111-120. doi: 10.1111/cei.13316. Epub 2019 Jun 6.

PMID:
31102558
14.

[Reactivation of tuberculosis during treatment with inhibitors of TNF].

Miossec P.

Rev Prat. 2018 May;68(5):537-540. French.

PMID:
30869425
15.

Activation of the Peroxisome Proliferator-Activated Receptor γ Coactivator 1β/NFATc1 Pathway in Circulating Osteoclast Precursors Associated With Bone Destruction in Rheumatoid Arthritis.

Ma JD, Jing J, Wang JW, Mo YQ, Li QH, Lin JZ, Chen LF, Shao L, Miossec P, Dai L.

Arthritis Rheumatol. 2019 Aug;71(8):1252-1264. doi: 10.1002/art.40868. Epub 2019 Jul 3.

16.

IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels.

Robert M, Miossec P.

Front Med (Lausanne). 2019 Jan 14;5:364. doi: 10.3389/fmed.2018.00364. eCollection 2018. Review.

17.

Blockade of Store-Operated Calcium Entry Reduces IL-17/TNF Cytokine-Induced Inflammatory Response in Human Myoblasts.

Beringer A, Gouriou Y, Lavocat F, Ovize M, Miossec P.

Front Immunol. 2019 Jan 14;9:3170. doi: 10.3389/fimmu.2018.03170. eCollection 2018.

18.

IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases.

Beringer A, Miossec P.

Autoimmun Rev. 2018 Dec;17(12):1176-1185. doi: 10.1016/j.autrev.2018.06.008. Epub 2018 Oct 12. Review.

PMID:
30321671
19.

Live-stream characterization of cadmium-induced cell death using visible CdTe-QDs.

Filali S, Geloën A, Lysenko V, Pirot F, Miossec P.

Sci Rep. 2018 Aug 22;8(1):12614. doi: 10.1038/s41598-018-31077-2.

20.

Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis.

Nguyen MVC, Baillet A, Romand X, Trocmé C, Courtier A, Marotte H, Thomas T, Soubrier M, Miossec P, Tébib J, Grange L, Toussaint B, Lequerré T, Vittecoq O, Gaudin P.

Joint Bone Spine. 2019 Mar;86(2):195-201. doi: 10.1016/j.jbspin.2018.05.006. Epub 2018 Jun 6.

PMID:
29885551
21.

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.

Bienvenu B, Cozon G, Mataix Y, Lachaud D, Alix A, Hoarau C, Antier D, Hachulla E, Brice S, Viallard JF, Tamisier S, Fauchais AL, Renon-Carron F, Clerson P, Fardini Y, Crave JC, Miossec P.

J Clin Immunol. 2018 May;38(4):503-512. doi: 10.1007/s10875-018-0507-x. Epub 2018 May 31.

22.

Differential effects of TNF-α and IL-1β on the control of metal metabolism and cadmium-induced cell death in chronic inflammation.

Bonaventura P, Lamboux A, Albarède F, Miossec P.

PLoS One. 2018 May 16;13(5):e0196285. doi: 10.1371/journal.pone.0196285. eCollection 2018.

23.

Synergistic effect of interleukin-17 and tumour necrosis factor-α on inflammatory response in hepatocytes through interleukin-6-dependent and independent pathways.

Beringer A, Thiam N, Molle J, Bartosch B, Miossec P.

Clin Exp Immunol. 2018 Aug;193(2):221-233. doi: 10.1111/cei.13140. Epub 2018 May 31.

24.

Cryoglobulins: An update on detection, mechanisms and clinical contribution.

Kolopp-Sarda MN, Miossec P.

Autoimmun Rev. 2018 May;17(5):457-464. doi: 10.1016/j.autrev.2017.11.035. Epub 2018 Mar 8. Review.

PMID:
29526627
25.

Inflammation in 2017: Connectivity to other fields brings new ideas.

Miossec P.

Nat Rev Rheumatol. 2018 Feb;14(2):65-66. doi: 10.1038/nrrheum.2017.215. Epub 2018 Jan 11. Review. No abstract available.

PMID:
29323346
26.

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.

Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S.

Ann Rheum Dis. 2018 Apr;77(4):523-532. doi: 10.1136/annrheumdis-2017-212127. Epub 2017 Dec 23.

27.

Modeling of the effects of IL-17 and TNF-α on endothelial cells and thrombus growth.

Bouchnita A, Miossec P, Tosenberger A, Volpert V.

C R Biol. 2017 Nov - Dec;340(11-12):456-473. doi: 10.1016/j.crvi.2017.10.002. Epub 2017 Nov 28.

28.

Early kinetics of serum Interleukine-17A and infarct size in patients with reperfused acute ST-elevated myocardial infarction.

Bochaton T, Mewton N, Thiam N, Lavocat F, Baetz D, Dufay N, Prieur C, Bonnefoy-Cudraz E, Miossec P, Ovize M.

PLoS One. 2017 Nov 22;12(11):e0188202. doi: 10.1371/journal.pone.0188202. eCollection 2017.

29.

Is undifferentiated spondyloarthritis a discrete entity? A debate.

Deodhar A, Miossec P, Baraliakos X.

Autoimmun Rev. 2018 Jan;17(1):29-32. doi: 10.1016/j.autrev.2017.11.006. Epub 2017 Nov 3. Review.

PMID:
29108820
30.

PUMA gene delivery to synoviocytes reduces inflammation and degeneration of arthritic joints.

Hong SS, Marotte H, Courbon G, Firestein GS, Boulanger P, Miossec P.

Nat Commun. 2017 Jul 27;8(1):146. doi: 10.1038/s41467-017-00142-1.

31.

Regulatory effects of zinc on cadmium-induced cytotoxicity in chronic inflammation.

Bonaventura P, Lamboux A, Albarède F, Miossec P.

PLoS One. 2017 Jul 25;12(7):e0180879. doi: 10.1371/journal.pone.0180879. eCollection 2017.

32.

Effects of Interleukin 17 on the cardiovascular system.

Robert M, Miossec P.

Autoimmun Rev. 2017 Sep;16(9):984-991. doi: 10.1016/j.autrev.2017.07.009. Epub 2017 Jul 10. Review.

PMID:
28705781
33.

Interleukin-25 Produced by Synoviocytes Has Anti-inflammatory Effects by Acting As a Receptor Antagonist for Interleukin-17A Function.

Lavocat F, Ndongo-Thiam N, Miossec P.

Front Immunol. 2017 May 31;8:647. doi: 10.3389/fimmu.2017.00647. eCollection 2017.

34.

Protective effect of low dose intra-articular cadmium on inflammation and joint destruction in arthritis.

Bonaventura P, Courbon G, Lamboux A, Lavocat F, Marotte H, Albarède F, Miossec P.

Sci Rep. 2017 May 25;7(1):2415. doi: 10.1038/s41598-017-02611-5.

35.

Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice.

Miossec P.

RMD Open. 2017 Feb 15;3(1):e000284. doi: 10.1136/rmdopen-2016-000284. eCollection 2017. Review.

36.

Selected cytokine pathways in rheumatoid arthritis.

Noack M, Miossec P.

Semin Immunopathol. 2017 Jun;39(4):365-383. doi: 10.1007/s00281-017-0619-z. Epub 2017 Feb 17. Review.

PMID:
28213794
37.

Relevance of C5b9 immunostaining in the diagnosis of neonatal hemochromatosis.

Dubruc E, Nadaud B, Ruchelli E, Heissat S, Baruteau J, Broué P, Debray D, Cordier MP, Miossec P, Russo P, Collardeau-Frachon S.

Pediatr Res. 2017 May;81(5):712-721. doi: 10.1038/pr.2017.8. Epub 2017 Jan 13.

PMID:
28085791
38.

IL-17, now an important target for treatment in arthritis!

Miossec P.

Joint Bone Spine. 2017 May;84(3):247-249. doi: 10.1016/j.jbspin.2016.12.001. Epub 2016 Dec 23. Review. No abstract available.

PMID:
28017822
39.
40.

Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles.

Coutant F, Miossec P.

Nat Rev Rheumatol. 2016 Dec;12(12):703-715. doi: 10.1038/nrrheum.2016.147. Epub 2016 Sep 22. Review.

PMID:
27652503
41.

T-cell clones from Th1, Th17 or Th1/17 lineages and their signature cytokines have different capacity to activate endothelial cells or synoviocytes.

Lavocat F, Maggi L, Annunziato F, Miossec P.

Cytokine. 2016 Dec;88:241-250. doi: 10.1016/j.cyto.2016.09.019. Epub 2016 Sep 28.

PMID:
27693917
42.

Medical applications of Cu, Zn, and S isotope effects.

Albarede F, Télouk P, Balter V, Bondanese VP, Albalat E, Oger P, Bonaventura P, Miossec P, Fujii T.

Metallomics. 2016 Oct 1;8(10):1056-1070. Review.

PMID:
27513195
43.

IL-17A and TNF-α Increase the Expression of the Antiapoptotic Adhesion Molecule Amigo-2 in Arthritis Synoviocytes.

Benedetti G, Bonaventura P, Lavocat F, Miossec P.

Front Immunol. 2016 Jun 27;7:254. doi: 10.3389/fimmu.2016.00254. eCollection 2016.

44.

Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion.

Noack M, Ndongo-Thiam N, Miossec P.

Arthritis Res Ther. 2016 Jun 23;18:148. doi: 10.1186/s13075-016-1046-6.

45.

Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells.

Noack M, Ndongo-Thiam N, Miossec P.

Clin Exp Immunol. 2016 Oct;186(1):64-74. doi: 10.1111/cei.12830. Epub 2016 Aug 9.

46.

Negative association between autoantibodies against IL-17, IL-17/anti-IL-17 antibody immune complexes and destruction in rheumatoid arthritis.

Ndongo-Thiam N, Clement A, Pin JJ, Razanajaona-Doll D, Miossec P.

Ann Rheum Dis. 2016 Jul;75(7):1420-2. doi: 10.1136/annrheumdis-2016-209149. Epub 2016 Apr 29. No abstract available.

PMID:
27130907
47.

Increased sensitivity of rheumatoid synoviocytes to Schnurri-3 expression in TNF-α and IL-17A induced osteoblastic differentiation.

Lavocat F, Osta B, Miossec P.

Bone. 2016 Jun;87:89-96. doi: 10.1016/j.bone.2016.04.008. Epub 2016 Apr 9.

PMID:
27072520
48.

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease.

Smolen JS, Collaud Basset S, Boers M, Breedveld F, Edwards CJ, Kvien TK, Miossec P, Sokka-Isler T, van Vollenhoven RF, Abadie EC, Bruyère O, Cooper C, Mäkinen H, Thomas T, Tugwell P, Reginster JY; European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Ann Rheum Dis. 2016 Jul;75(7):1268-71. doi: 10.1136/annrheumdis-2016-209429. Epub 2016 Apr 1. Review.

49.

A Feedback Loop between Inflammation and Zn Uptake.

Bonaventura P, Lamboux A, Albarède F, Miossec P.

PLoS One. 2016 Feb 4;11(2):e0147146. doi: 10.1371/journal.pone.0147146. eCollection 2016.

50.

IL-17 in Chronic Inflammation: From Discovery to Targeting.

Beringer A, Noack M, Miossec P.

Trends Mol Med. 2016 Mar;22(3):230-241. doi: 10.1016/j.molmed.2016.01.001. Epub 2016 Jan 31. Review.

PMID:
26837266

Supplemental Content

Loading ...
Support Center